Gregory Botta

[UC San Diego Health Moores Cancer Center @UCSDCancer]

In Hwan Park presents “Peptide-delivered low-dose IL-2 reprograms pancreatic cancer immunity to improve survival,” highlighting a novel immunotherapeutic strategy aimed at reshaping the tumor immune microenvironment in pancreatic cancer.

If you caught Dr. Botta’s interview yesterday, he also discussed this study and its significance in advancing immune-based approaches in hard-to-treat cancers.

AACR 2026 Annual Meeting
Section 43, Poster 18
#AACR26
@AACRFoundation

[UC San Diego Health Moores Cancer Center @UCSDCancer]

Greg Botta, MD, PhD (@gregorybotta) and In Hwan Park, Staff Research Associate at the Moores Cancer Center, present their work today and tomorrow on “Peptide-delivered low-dose IL-2 reprograms pancreatic cancer immunity to improve survival” (Section 43, Board 18).

Their research explores how immune modulation — particularly targeting tumor-associated macrophages — can reshape the tumor microenvironment and advance new therapeutic strategies in pancreatic cancer.

#AACR2026 @AACRFoundation

[Gregory Botta @gregorybotta]

Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer
https://t.co/E6CPfAV7PP

[UC San Diego Health Moores Cancer Center @UCSDCancer]

💡 With a $1 million grant from @TheVFoundation, Moores Cancer Center and @salkinstitute are changing the course of pancreatic cancer treatment.

Dr. Gregory Botta is collaborating with Salk's Diana Hargreaves to improve immunotherapy treatments, identify potential biomarkers and elevate patient outcomes.

🔗 Read more: https://t.co/Zie6HihHch

[Gregory Botta @gregorybotta]

@Aiims1742 @skopetz @DrShubhamPant @DavidHongMD Every vehicle on the island!

[Gregory Botta @gregorybotta]

Our expert team's new publication on the Association of personalized and tumor-informed #ctDNA with patient survival outcomes in #pancreaticcancer
https://t.co/oME9GyvpDT

@UCSDCancer

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC case report: Metastatic gastric cancer target lesion complete response with Claudin18.2-CAR T cells https://t.co/Z14vOJgqRV @gregorybotta @Kaufm020 @DrEzraCohen

[Gregory Botta @gregorybotta]

Metastatic gastric cancer target lesion complete response with Claudin18.2-CAR T cells | Journal for ImmunoTherapy of Cancer https://t.co/kCUAvSFzkX

[Diane M. Simeone, MD @MadameSurgeon]

It’s official! It is my absolute privilege to be named as the Director of the Moores Comprehensive Cancer Center at UCSD Health. I am looking forward to advancing efforts in cancer based on an approach of collaboration and excellence.

[Bryan Clary @clary_bryan]

UCSD Faculty member, Dr. Andy Lowy delivering the MSKCC David Rubenstein Award Lecture in New York City. Prestigious award given annually for impacting the understanding, diagnosis and/t management of pancreatic cancer eradication Congratulations Dr. Lowy!

[Total Health™ @TotalHealthConf]

Day 1 at #ESMOWest2023 was a blast! 🚀

A special thank you to our fantastic speakers today for sharing their incredible expertise!

@marklewismd
@gregorybotta
@Dr_RaviMadan
@marcellorotta1
@MikeLattanzi
@drkomanduri
@bvantine1

#MedEd #Oncology #MedTwitter

[Razelle Kurzrock, MD @Dr_R_Kurzrock]

Honored to chair this outstanding conference. 💥🔥🌈🎯
Nigel and Deanna Russell at Genome Web did a great job.
The speakers were so incredible that people were not looking at their iPhones.
Bring together academia, industry, patients to transform precision oncology

[Gregory Botta @gregorybotta]

https://t.co/heAkJKXlzH

[Gregory Botta @gregorybotta]

@PatelOncology ctDNA has the potential to differentiate radiologic progression vs flare: https://t.co/ECJJPxPWc3

[Cosimo Commisso @Cosimo_Commisso]

Plus chat with GI medical oncologist @gregorybotta from @UCSDCancer and pancreatic cancer survivor Russ Gold @Justice_in_SD @PanCANSanDiego Register now! See you there!

[Pashtoon Kasi MD, MS @pashtoonkasi]

🆕Just published🗞️
One of the 1st insights on🩸#ctDNA in patients with #AnalCancer. Of value in a number of ways & clinical settings with how the field is evolving including use of #immunotherapy➕deeper insights from sequencing🧬.
@OncoAlert @OncJournal
https://t.co/zhY3X2NyYj

[Brandon Huffman, MD @BHuffmanMD]

Happy to share our publication on tumor-informed circulating tumor DNA in patients with gastric, GEJ, and esophageal cancers. See our @JCOPO_ASCO manuscript out today: https://t.co/63RnOisFeZ #ctDNA

[Pashtoon Kasi MD, MS @pashtoonkasi]

👇🏾🆕 @JCOPO_ASCO
Delighted to be a part of this important project - one of the largest datasets providing in-depth insights & analyses into #ctDNA🩸🧬 in stomach & esophageal cancers. #STCSM #ESOCSM

➡️Sets the foundation for #MRD-driven📚. @OncoAlert

📌https://t.co/LIYFNqNaF1

[Gregory Botta @gregorybotta]

https://t.co/VXVA6YhTqc

[Gregory Botta @gregorybotta]

https://t.co/tSqYueNAxQ